Monday, January 11, 2016

Dilantin Stevens Johnson Syndrome Rash Explored

Zartontin Stevens Johnson Syndrome

Popular antiepileptic drug Dilantin (phenytoin) has been frequently linked to the devastating skin condition known as Stevens Johnson Syndrome (SJS).

SJS, a life-threatening allergic reaction, is often characterized by red or purple skin lesions and leaving permanent skin damage or blindness.

According to a recent study that included 15 American burn units, over 20 percent of Toxic Epidermal Necrolysis (TEN) cases, the more severe form of SJS, are linked to Dilantin prescriptions.

While Stevens Johnson Syndrome can occur from most medications, the strong association between the condition and Dilantin has been a concern for several years.

Approved in 1953 and manufactured by Pfizer, Dilantin is often prescribed to patients suffering from various forms of epilepsy. It works by slowing down the electrical signals in the brain, which helps the brain control the body’s impulses.

This medication is one of the most commonly prescribed antiepileptic drugs in the United States but has been criticized multiple times for its severe side effects.

Overview of Dilantin SJS Complications

Dilantin-induced SJS has been reported since the 1930s, with it being estimated that 15 percent of all SJS cases ending up deadly. Stanford Hospital estimates that one in 10,000 patient Dilantin prescriptions result in a serious case of Dilantin SJS, with survivors often exhibiting skin scarring.

The skin lesions mentioned earlier often cause the skin to detach and shed off the body, which exposes inner tissue and muscle to potential infection. Stevens Johnson Syndrome is an extremely rare condition that is, sadly, often diagnosed after the condition progresses to a dangerous stage.

Early signs of Stevens Johnson Syndrome include flu symptoms and will occur within the first two to eight weeks of starting the medication. When the lesions appear the patient’s condition often deteriorates rapidly, which can lead to internal organ damage, throat swelling, and other dangerous symptoms.

Due to the nature of these injuries, SJS patients are often treated in the burn unit of hospitals. Up to 30 percent of the skin peels off of patients suffering from Stevens Johnson Syndrome, while TEN patients can lose more than 30 percent of their skin.

After years of Dilantin SJS reports, the FDA released a public warning regarding the alleged link in 2008. The warning went on further to say that patients of Asian and African ancestry may be at higher risk for developing SJS, along with patients who may be sensitive to medications.

Despite the severity of these complications, Pfizer has repeatedly denied that there is a correlation between their drug and the condition. Pfizer has been subjected to multiple Dilantin SJS lawsuits over the years, along with eight other pharmaceutical companies that produce generic Dilantin.

Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The SJS attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Dilantin class action lawsuit is best for you. [In general, Dilantin lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.

Learn More

We tell you about cash you can claim EVERY WEEK! Sign up for our free newsletter.

  • Email*
  • State*
    selectAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed Forces Pacific


jQuery(document).ready(function($){gformInitSpinner( 5, ‘http://11284-presscdn-0-40.pagely.netdna-cdn.com/wp-content/plugins/gravityforms/images/spinner.gif’ );jQuery(‘#gform_ajax_frame_5’).load( function(){var contents = jQuery(this).contents().find(‘*’).html();var is_postback = contents.indexOf(‘GF_AJAX_POSTBACK’) >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find(‘#gform_wrapper_5’);var is_confirmation = jQuery(this).contents().find(‘#gform_confirmation_wrapper_5’).length > 0;var is_redirect = contents.indexOf(‘gformRedirect(){‘) >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;if(is_form){jQuery(‘#gform_wrapper_5’).html(form_content.html());setTimeout( function() { /* delay the scroll by 50 milliseconds to fix a bug in chrome */ jQuery(document).scrollTop(jQuery(‘#gform_wrapper_5’).offset().top); }, 50 );if(window[‘gformInitDatepicker’]) {gformInitDatepicker();}if(window[‘gformInitPriceFields’]) {gformInitPriceFields();}var current_page = jQuery(‘#gform_source_page_number_5’).val();gformInitSpinner( 5, ‘http://11284-presscdn-0-40.pagely.netdna-cdn.com/wp-content/plugins/gravityforms/images/spinner.gif’ );jQuery(document).trigger(‘gform_page_loaded’, [5, current_page]);window[‘gf_submitting_5’] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find(‘#gforms_confirmation_message_5’).html();if(!confirmation_content){confirmation_content = contents;}setTimeout(function(){jQuery(‘#gform_wrapper_5’).replaceWith(” + confirmation_content + ”);jQuery(document).scrollTop(jQuery(‘#gforms_confirmation_message_5’).offset().top);jQuery(document).trigger(‘gform_confirmation_loaded’, [5]);window[‘gf_submitting_5’] = false;}, 50);}else{jQuery(‘#gform_5’).append(contents);if(window[‘gformRedirect’]) {gformRedirect();}}jQuery(document).trigger(‘gform_post_render’, [5, current_page]);} );} ); if(typeof gf_global == ‘undefined’) var gf_global = {“gf_currency_config”:{“name”:”U.S. Dollar”,”symbol_left”:”$”,”symbol_right”:””,”symbol_padding”:””,”thousand_separator”:”,”,”decimal_separator”:”.”,”decimals”:2},”base_url”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms”,”number_formats”:[],”spinnerUrl”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms\/images\/spinner.gif”};jQuery(document).bind(‘gform_post_render’, function(event, formId, currentPage){if(formId == 5) {gformInitChosenFields(‘#input_5_2′,’No results matched’);} } );jQuery(document).bind(‘gform_post_conditional_logic’, function(event, formId, fields, isInit){gformInitChosenFields(‘#input_5_2′,’No results matched’);} ); jQuery(document).ready(function(){jQuery(document).trigger(‘gform_post_render’, [5, 1]) } );

Get Help – It’s Free

Help for Victims of Stevens Johnson Syndrome

If you or a loved one were diagnosed with Stevens Johnson Syndrome (SJS) or toxic epidermal necrolysis (TEN) after taking a prescribed or over-the-counter medication, you may be eligible to take legal action against the drug’s manufacturer. Filing an SJS lawsuit or class action lawsuit may help you obtain compensation for medical bills, pain and suffering, and other damages. Obtain a free and confidential review of your case by filling out the form below.

An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.

  • First Name*
  • Last Name*
  • Street Address*
  • Apt. #
  • City*
  • State*
    AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed Forces Pacific
  • Zip Code*
  • Phone*
  • Email*
  • Please list an emergency contact's name and phone number:*
  • What is the best time to call you?*
  • Were you, or a loved one, medically diagnosed with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis?*
    YesNo
  • What year(s) were you or your loved one diagnosed with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis?*
  • Please select which symptoms you or your loved one were medically diagnosed with:*
    • Stevens-Johnson Syndrome

    • Toxic Epidermal Necrolysis

    • No injury

    • Not Listed (please detail the symptoms in the comments section if this is selected.)

  • Please enter any additional details you would like the staff reviewing your submission to know.*
  • Have you already retained an attorney to file a Stevens-Johnson Syndrome lawsuit or a Toxic Epidermal Necrolysis lawsuit?*
    NoYes
  • I understand and agree that submitting this form does not create an attorney-client relationship and that the information I submit is not confidential or privileged and may be shared.*
    • Yes

  • ¿Necesita un orador espaƱol?
    • Yes
    • No

if(typeof gf_global == ‘undefined’) var gf_global = {“gf_currency_config”:{“name”:”U.S. Dollar”,”symbol_left”:”$”,”symbol_right”:””,”symbol_padding”:””,”thousand_separator”:”,”,”decimal_separator”:”.”,”decimals”:2},”base_url”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms”,”number_formats”:[],”spinnerUrl”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms\/images\/spinner.gif”};jQuery(document).bind(‘gform_post_render’, function(event, formId, currentPage){if(formId == 16) {gformInitChosenFields(‘#input_16_5′,’No results matched’);if(!/(android)/i.test(navigator.userAgent)){jQuery(‘#input_16_7’).mask(‘(999) 999-9999’).bind(‘keypress’, function(e){if(e.which == 13){jQuery(this).blur();} } );}} } );jQuery(document).bind(‘gform_post_conditional_logic’, function(event, formId, fields, isInit){gformInitChosenFields(‘#input_16_5′,’No results matched’);} ); jQuery(document).ready(function(){jQuery(document).trigger(‘gform_post_render’, [16, 1]) } );

The post Dilantin Stevens Johnson Syndrome Rash Explored appeared first on Top Class Actions.

from http://topclassactions.com/lawsuit-settlements/lawsuit-news/259226-the-problem-of-dilantin-sjs-explored/


No comments:

Post a Comment